ApprovedFDA approval

Baxfendy (baxdrostat)

AstraZeneca (AZN)

Marketer take

An aldosterone synthase inhibitor for add-on hypertension, a crowded primary-care market where payer access drives uptake, and Mineralys' lorundrostat decision on Dec 22, 2026 sets up a same-class rival.

Sponsor company
AstraZeneca (AZN)
Indication
To treat hypertension in combination with other antihypertensive drugs
Therapeutic area
Cardiovascular
Event
FDA approval
Date
May 15, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move